Revance Therapeutics Inc (NASDAQ:RVNC)
| 31.07 Delayed Data As of Jun 02 |  +0.66 / +2.17%Today’s Change | 11.27 Today|||52-Week Range 37.98 | +68.31% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Revenue and Income | Net Revenues | 300.0K | 300.0K | 262.0K | 3.7M | |
| Depreciation And Amortization | 2.0M | 1.4M | 1.5M | 1.7M | ||
| Operating Expenses | Gross Income | -1.7M | -- | -- | -- | |
| General Expenses | 70.6M | 78.0M | 116.3M | 144.6M | ||
| Research And Development | 47.5M | 50.4M | 80.4M | 92.5M | ||
| Total Operating Expenses | 72.6M | 79.5M | 117.8M | 146.4M | ||
| Non-Operating Expenses | Operating Income | -72.3M | -79.2M | -117.5M | -142.6M | |
| Extraordinary Credit | 127.0K | 0.00 | 0.00 | 0.00 | ||
| Extraordinary Charge | 0.00 | -9.7M | -3.5M | -140.0K | ||
| Interest Expense On Debt | 1.2M | 1.1M | 570.0K | 44.0K | ||
| Other Expenses | -327.0K | -535.0K | -525.0K | -773.0K | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -73.5M | -89.3M | -120.6M | -139.6M | |
| Income Taxes | 0.00 | 0.00 | 0.00 | -3.0M | ||
| Net Income | -73.5M | -89.3M | -120.6M | -142.6M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 24.3M | 28.1M | 30.1M | 36.2M | |
| Shares To Calculate EPS Diluted | 24.3M | 28.1M | 30.1M | 36.2M | ||
| Earnings Per Share | EPS | -$3.02 | -$3.18 | -$4.01 | -$3.94 | |
| EPS Diluted | -$3.02 | -$3.18 | -$4.01 | -$3.94 | ||
